Por el momento, a la espera de estudios que comparen la semaglutida y la tirzepatida , disponemos de un metanlisis* de ambos frmacos que incluye un total de 22 ensayos clnicos aleatorizados, con 18472 participantes, que concluye que la tirzepatida es superior en el control de la glucemia y en la reduccin del peso a la semaglutida subcutnea
By drug class, the Glucagon like peptide-1 (GLP-1) receptor agonist segment is accounted for a 41.9% revenue share in 2023
Brand-Name FDA-Approved Medications Referenced on altRx altRx's source materials also reference brand-name FDA-approved medications at separate listed price points: Mounjaro: Listed at $1,249 per month per altRx's source materials Ozempic: Listed at $1,149 per month per altRx's source materials Wegovy: Listed at $1,579 per month per altRx's source materials Zepbound: Listed at $1,249 per month per altRx's source materials According to altRx's published trademark notice, Wegovy is FDA-approved for weight loss, and Ozempic is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss at the discretion of a clinician
The most popular trial for Ozempic was the SUSTAIN-6 trial published in 2016, which showed that participants receiving weekly Ozempic (semaglutide) lost an average of 3-5 kg (8-11 lbs) after two years (3)
Yes but the full picture is a little more nuanced than that
